S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer
Status:
Unknown status
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Although there has been some progress in chemotherapy for metastatic gastric cancer, no
standard regimen of adjuvant chemotherapy is available, and many clinical trials have
produced contradictory results. The majority of randomized clinical trials studying adjuvant
chemotherapy in gastric cancer have been underpowered, involved low-volume centers, or used
ineffective chemotherapy regimens. As a result, well-designed multicenter trials are still
needed. The ACTS-GC trial, which demonstrated the efficacy of S-1 for stage II-III gastric
cancer patients who underwent curative resection with extended lymph-node dissection (D2),
may be valid in countries where D2 surgery is considered the standard of care. S-1 improved
the 3-year overall survival from 70.1% for surgery alone to 80.1%. However, 3-year overall
survival in stage IIIA and stage IIIB patients receiving S-1 were 77.4% and 63.4%,
respectively, which are less satisfactory compared to the rate for stage II (90.7%). Based on
the unsatisfactory outcome among later stage patients in the ACTS-GC adjuvant trial, further
investigation is needed for more effective postoperative treatment of patients with stage
IIIB and IV (M0) cancer. Therefore, the researchers investigated the efficacy and safety of
S-1 versus S-1 plus cisplatin as adjuvant chemotherapy in patient with curatively resected
gastric adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Kyungpook National University Kyungpook National University Hospital